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IFN: Interferon, 
IL: Interleukin, 
LPS: Lipopolysaccharide, 
MHC: Major Histocompatibility Complex, 
NO: Nitric oxide, 
TGF: Transforming Growth Factor, 
TLR: Toll-like receptor, 
TNF: Tumor Necrosis Factor 
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ABSTRACT 
Ibrutinib (PCI-32765) is an irreversible dual Btk/Itk inhibitor shown to be effective in 
treating several B cell malignancies. However, limited studies have been conducted to 
study the effect of this drug on myeloid cell function. Hence, we studied the effect of 
D
ow
nl
oa
de
d 
by
 [O
hio
 St
ate
 U
niv
ers
ity
 L
ibr
ari
es
], 
[G
ay
ath
ri 
Na
tar
aja
n] 
at 
12
:26
 09
 Ju
ne
 20
15
 
 3 
 
ibrutinib treatment on TLR-4 mediated activation of bone marrow derived dendritic cell 
culture (DCs). Upon ibrutinib treatment, LPS-treated DCs displayed lower synthesis of 
TNF-α and nitric oxide and higher induction of IL-6, TGF-β, IL-10 and IL-18. While 
ibrutinib dampened MHC-II and CD86 expression on DCs, CD80 expression was 
upregulated. Further, ibrutinib-treated DCs promoted T cell proliferation and enhanced 
IL-17 production upon co-culture with nylon wool enriched T cells. Taken together, our 
results indicate that ibrutinib modulates TLR-4 mediated DC activation to promote an IL-
17 response. We describe a novel mode of action for ibrutinib on DCs which should be 
explored to treat other forms of cancer besides B cell malignancies. 
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INTRODUCTION 
Ibrutinib is a potent irreversible inhibitor of Tec kinases, Btk1 and Itk2. Extensive studies 
have demonstrated that ibrutinib effectively treats a variety of hematological 
malignancies3–7. Additionally, its efficacy against immune complex disease models 
where myeloid cells such as neutrophils, monocytes, macrophages and dendritic cells 
mediate chronic inflammation suggests that ibrutinib may also target myeloid cells8. Btk 
is expressed in different cell types within the myeloid lineage such as dendritic cells 
(DCs) and macrophages9,10. Further, Btk enhances innate immune responses, 
participates in TLR-4 mediated myeloid cell activation9,11–14 and also enables DCs to 
regulate T cell proliferation and differentiation9. Although ibrutinib has been shown to 
have varied effects on B cells, T cells and NK cells1,5–8, its effect on myeloid cells is still 
incompletely understood. Since DCs play a critical role in initiating and directing 
protective T cell responses during cancer15,16, we wanted to study how ibrutinib affects 
the activation of DCs and their ability to prime T cell responses. Therefore, we 
determined the impact of ibrutinib treatment on DC culture and subsequent T cell 
activation using an in vitro model of murine bone marrow derived dendritic cells. 
 
RESULTS AND DISCUSSION 
Ibrutinib treatment alters cytokine and nitric oxide responses in LPS-treated DCs 
Ligands to Toll-like receptors (TLRs) are potent activators of DCs and are being 
evaluated as adjuvants for dendritic cell based cancer therapies15. Further, it is known 
that Btk participates in TLR signaling in myeloid cells including DCs9–14. Hence, we 
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studied how ibrutinib affects immune responses in TLR-activated DCs using 
lipopolysaccharide (LPS), a TLR-4 ligand, as an immunogen for our studies. We 
examined whether ibrutinib modulates cytokine and nitric oxide (NO) production in DCs 
upon LPS stimulation. We studied these responses at various time points after LPS 
stimulation and at different concentrations of ibrutinib. LPS/ibrutinib-treated DCs 
dampened TNF-α production compared to LPS/control-treated DCs (Fig. 1A), while IL-
12 production was comparable between both groups (Fig. 1C). There was reduced NO 
production in LPS/ibrutinib-treated DCs at a later time point compared to LPS/control-
treated DCs (Fig. 1B). Additionally upon ibrutinib treatment there was higher induction of 
IL-18, an increase in IL-6 and TGF-β at earlier time points of LPS stimulation, and an 
increase in IL-10 at a later time point compared to controls (Fig. 2A-D). The differences 
for IL-6, IL-10, IL-18 and NO were observed to be greatest mostly at the higher 
concentration of ibrutinib (Fig. 1 and Fig. 2). Taken together, our results indicate that 
ibrutinib decreases TNF-α and NO production, increases the expression of IL-6, IL-10, 
IL-18 and TGF-β and does not alter IL-12 production upon LPS stimulation (Fig. 1 and 
Fig. 2). Our observations for reduced TNF-α and NO is consistent with previous reports 
of deficient TNF-α and NO in LPS stimulated myeloid cells from Btk-/- mice and XID 
mice which have a mutation in the PH domain of Btk that interferes with normal Btk 
signaling11–14. Enhanced IL-6 production has also been reported in LPS stimulated Btk-/- 
macrophages11. Further, a recent study comparing LPS-mediated cytokine production in 
WT and Btk-/- DCs supports some of our observations. The authors reported a decrease 
in TNF-α production in Btk-/- mice and increase in IL-10 production by Btk-/- DCs17. 
However, there were contrasting differences in cytokines such as IL-6, IL-12 and IL-18 
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compared to the cytokine responses observed upon Btk inhibition with ibrutinib in our 
system. The authors observed lower IL-12 and IL-18 production by Btk-/- DCs while 
there were no differences in IL-6 production. We noted that the authors employed a 
different method of DC generation compared to our studies. The authors generated DCs 
by culturing bone marrow cells in the presence of Flt3L while we generated DCs in the 
presence of GMCSF for our studies. Previous reports have demonstrated that Flt3L and 
GMCSF promote the development of different subsets of DCs18,19. Further, Flt3L- and 
GMCSF-derived DCs also differ in their profiles of cytokine production in response to 
LPS activation19. It is possible that Btk differentially modulates TLR-4 signaling in Flt3L- 
and GMCSF-derived DCs and thereby, mediates different cytokine responses in these 
DC subsets. Taken together, our results indicate that ibrutinib alters TLR-4 mediated 
cytokine and NO production in DCs. These changes in cytokine responses upon 
ibrutinib treatment on DCs could subsequently reprogram T cell responses.   
Treatment with ibrutinib modulates the expression of MHC-II and co-stimulatory 
molecules on LPS-stimulated DCs 
Since LPS treatment upregulates the expression of MHC-II and co-stimulatory 
molecules in DCs20, we wanted to determine how ibrutinib affects the expression of 
these molecules in LPS-stimulated DCs. Ibrutinib treatment reduced the percentage of 
MHC-II+ and CD86+ cells and increased the percentage of CD80+ cells compared to 
control treatment in LPS-stimulated DCs (Fig. 3A-C). Further, LPS/ibrutinib-treated DCs 
displayed lower levels of MHC-II and CD86 expression and higher CD80 expression 
compared to LPS/control-treated DCs (Fig. 3D-F). However, percentages of CD40+ DCs 
and expression levels of CD40 remained similar between LPS/ibrutinib- and 
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LPS/control-treated DCs (data not shown).  It has been previously shown that IL-6 and 
TGF-β dampen the surface expression of MHC-II and co-stimulatory molecules21,22. 
Hence, it is possible that the increased production of IL-6 and TGF-β in ibrutinib-treated 
DCs (Fig. 2A and 2D) contributes to the reduction of MHC-II and CD86 expression in 
these cells. 
Ibrutinib-treated DCs promote an IL-17 response upon culture with T cells 
DC-derived cytokines such as IL-6, IL-18 and TGF-β are critical in initiating and 
directing IL-17 production by T cells20. Based on the cytokine profile generated upon 
ibrutinib treatment (Fig. 1 and 2), we hypothesized that ibrutinib-treated DCs would 
promote an IL-17 response from T cells. We investigated this by using an in vitro 
antigen-specific DC:T cell co-culture model. T cells co-cultured with LPS/ibrutinib-
treated DCs displayed higher proliferation rates compared to T cells co-cultured with 
LPS/control-treated DCs (Fig. 4A). We also evaluated the production of T cell cytokines 
in the co-culture supernatants. LPS/ibrutinib-treated DCs enhanced the production of IL-
17, but not IFN-γ or IL-13 compared to LPS/control-treated DCs (Fig. 4B-D). We could 
not detect the presence of IL-4 in either treatment (data not shown).  
The balance of cytokines and co-stimulatory molecules expressed by DCs determines 
the T-helper subset generated during T cell differentiation. The production of both IL-6 
and TGF-β by DCs promotes IL-17 production by T cells. Further, IL-17 synthesis by T 
cells can also be mediated by other cytokines such as IL-1820, which we observed to be 
increased in LPS/ibrutinib-treated DCs (Fig. 2C). Although CD80-CD86/CD28-CTLA4 
mediated co-stimulation has been suggested by some researchers to suppress IL-17 
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production by T cells23,24, our studies suggest that differential regulation of CD80 and 
CD86 expression may complement the cytokine signals driving IL-17 synthesis by T 
cells. Taken together, our results indicate that ibrutinib modulates DC activation and 
thereby promotes an IL-17 response by T cells. 
The precise role of IL-17 response in cancer immunity is still being evaluated with 
studies indicating that IL-17 plays both pro-tumor as well as anti-tumor roles depending 
on the type of cancer25. In a murine melanoma model, Th17 immune response was 
more effective than Th1 immune response in rejecting melanoma tumors26. In this 
model, Th17 cells activated tumor specific CD8+ T cells and promoted the recruitment of 
dendritic cells into tumor sites27. Alternatively, in healthy individuals and patients with 
indolent Chronic Lymphocytic Leukemia (CLL), the frequency of IL-17 producing T cells 
was higher and inversely correlated with immunosuppressive T cells such as regulatory 
T cells (Tregs) which are found at relatively higher frequency in progressive CLL 
patients28. This suggests that IL-17 may play a protective role in the pathogenesis of 
CLL. The frequency of IL-17 producing T cells was higher in mice with reduced tumor 
burden with primary intraocular B-cell lymphoma29 and increased IL-17 in the tumor 
microenvironment was associated with improved clinical survival in patients with ovarian 
cancer30. Such studies provide a rationale for the development of IL-17 based 
immunotherapies for the treatment of certain types of cancer. TLR-activated DCs are 
being studied for their potential anti-cancer effects due to their ability to generate potent 
T cell immune responses against various hematological malignancies and solid 
tumors15,31. We propose that ibrutinib should be further explored for its use in DC-based 
therapies due to its ability to modulate DC function and enhance DC-mediated T cell 
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responses in a TLR-dependent manner. Our results also reveal a new mode of action 
for ibrutinib on DCs besides its previously known effects on B cells, T cells and NK 
cells1,5–8. Hence, the effects of ibrutinib on DCs and other myeloid cell populations must 
be further elucidated, especially in diseases where ibrutinib is currently being employed 
for treatment. 
 
MATERIALS AND METHODS 
Mice strains 
Female C57BL/6 (age 8-10 weeks) and OT-II TCR transgenic mice (age 8-10 weeks) 
were purchased from Harlan and Jackson Laboratories respectively. All animals were 
housed in a pathogen-free animal facility in The Ohio State University in accordance 
with National Institutes of Health and institutional guidelines. 
Cultivation and stimulation of bone marrow derived dendritic cells 
Bone marrow derived DCs from C57BL/6 mice were cultivated as described 
previously32,33. Briefly, bone marrow cells were isolated from femurs and tibias of mice, 
treated with ACK lysis buffer and plated @ 5 million cells/ plate in sterile 100 x 15 mm 
vented petri dishes along with complete RPMI medium supplemented with 10% fetal 
bovine serum (Atlanta Biologicals), 1% penicillin (20 Units/ml)/streptomycin (20 µg/ml) 
(Life Technologies) and 20ng/ml GMCSF (Peprotech) for 6 days. At Day 6, cells from 
DC culture were collected by gently harvesting the floating fraction of cells to obtain > 
75% purity of CD11c+ DCs in the floating fraction. The remaining cells in the floating 
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fraction did not display lineage specific markers for T cells, B cells, NK cells and 
macrophages upon flow cytometric analysis. A small percentage of neutrophils were 
observed (approximately 6-8% of total cell population). However, these cells were short-
lived and were observed to die when the DC culture was seeded in 24-well plates 
(Corning Life Sciences) and rested for 24 hours prior to subsequent ibrutinib treatment 
and activation studies. For LPS activation studies, rested DCs were washed once with 
1X PBS (Life Technologies), treated with DMSO (control), 1 µM ibrutinib or 10 µM 
ibrutinib (Pharmacyclics, Inc.) for 30 minutes, washed twice with 1X PBS and treated 
with 1 µg/ml LPS (Sigma Aldrich) at 37ºC and 5% CO2. After 4, 12 and 24 hours of LPS 
treatment, RNA was extracted from cells for real-time PCR analysis and cell culture 
supernatants were harvested to determined cytokine and nitric oxide production. Further 
at 24 hour time point, cells were isolated for flow cytometric analysis.  
T cell co-culture and proliferation studies 
Rested DCs were treated with control or 1µM ibrutinib as mentioned above, pulsed with 
10 µg/ml OVA-peptide (323-339) (Anaspec) for 2 hours and treated with 1 µg/ml LPS 
(Sigma Aldrich) for 22 hours. After OVA/LPS stimulation, DCs were washed twice with 
1X PBS and cultured with CFSE-stained T cells from OT-II mice. Prior to culture with 
OVA/LPS-stimulated DCs, T cells were enriched from total splenocytes of OT-II mice by 
nylon wool enrichment as described previously34. Briefly, single cell suspensions were 
prepared from spleens from OT-II mice in complete RPMI medium supplemented with 
10% fetal bovine serum (Atlanta Biologicals), 1% penicillin (20 Units/ml)/streptomycin 
(20 µg/ml) (Life Technologies), treated with ACK Lysis buffer and incubated in nylon 
wool columns for one hour. After incubation, cells were eluted from the column, washed 
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with 1X PBS, stained with 5µM CFSE (Life Technologies) and cultured with OVA, 
OVA/Ibrutinib, OVA/LPS and OVA/LPS/Ibrutinib-treated DCs in 1:4 ratio for 5 days. 
After 5 days, T cell proliferation was evaluated by flow cytometry and culture 
supernatants were harvested to determine the concentration of cytokines by ELISA. 
 
Real-time PCR analysis 
Total RNA from LPS-stimulated DCs was extracted by adding TRIzol reagent to cells 
(Life Technologies) and performing chloroform-isopropanol extraction of RNA according 
to the manufacturer’s protocol. RNA was washed with 75% ethanol and resuspended in 
1X TE buffer (Life Technologies). RNA concentration was determined by absorbance at 
260nm. One µg RNA was used for first strand cDNA synthesis with SuperScript VILO 
cDNA synthesis kit (Invitrogen). Primer sequences and cycling conditions were obtained 
from PRIMER BANK35. PCR amplification was conducted in an Opticon Real-Time PCR 
cycler (Biorad) using SYBR Green (BioRad) for detection. Data were normalized to β-
actin and represented as fold induction over control-treated cells by ∆∆CT method. 
Cytokine ELISA 
Cytokine ELISA was performed on culture supernatants of LPS-stimulated DCs and 
DC-T cell co-cultures as described previously34. Briefly, purified anti-mouse TNF-α, IL-
12, IFN-γ, IL-17 (Biolegend) and IL-13 (eBiosciences) monoclonal antibodies were used 
as capture antibodies for the respective ELISA. Recombinant mouse TNF-α, IL-12, IFN-
γ, IL-13 (BD Biosciences) and IL-17 (eBiosciences) were used as standards. Detection 
of cytokines was performed using biotinylated anti-mouse antibodies for TNF-α, IL-12, 
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IFN-γ, IL-17 (Biolegend) and IL-13 (eBiosciences), streptavidin conjugated alkaline 
phosphatase (BD Pharmingen) and p-nitrophenyl phosphate (PNPP) tablets (Thermo 
Fisher Scientific) as substrate. Plates were read using Spectramax M3 microplate 
reader (Molecular Devices LLC) at an absorbance of 405 nm. Cytokine concentrations 
were determined by extrapolation from the generated standard curve using Softmax Pro 
software (Molecular Devices LLC).  
Nitric oxide assay 
Culture supernatants of LPS-stimulated DCs were tested for the presence of nitric oxide 
as described previously36. Briefly, nitrite was measured in culture supernatants using 
Griess Reagent (Sigma Aldrich) with sodium nitrite as the standard. Plates were read 
using a Spectramax M3 microplate reader (Molecular Devices LLC) at the absorbance 
of 570 nm. The concentrations of nitric oxide were determined by extrapolation of 
generated standard curves using Softmax Pro software (Molecular Devices LLC). 
Flow cytometry 
LPS-stimulated DCs were washed with 1X PBS, blocked using normal mouse serum 
and incubated with conjugated antibodies against various cell surface markers including 
CD11c, MHC-II, CD80 and CD86 (Biolegend). Cells from co-cultures assays were 
washed and blocked as mentioned above and incubated with conjugated antibody 
against CD4 (Biolegend). Samples were acquired on a BD FACS Calibur (BD 
Biosciences). Data analysis was performed using FlowJo software (Tree Star, Inc.). 
During analysis, gating was performed based on respective isotype controls for the 
corresponding conjugated antibody. Analysis of surface marker expression on DCs was 
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performed by gating on CD11c+ cells. Percentage of proliferating cells in T cell co-
culture assay was measured on CD4+ T cells using the Proliferation platform in the 
FlowJo software.  
 
Statistical analysis 
All statistical analyses were done using Prism 5 (GraphPad Software). Student’s 
unpaired t test was employed to determine statistical significance of values obtained. 
The p values less than 0.05 were considered statistically significant.  
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Figure 1. Ibrutinib dampens TNF-α and nitric oxide production in dendritic cells upon 
LPS stimulation. (A) TNF-α, (B) nitric oxide (NO) and (C) IL-12 production in control- 
and ibrutinib-treated DCs stimulated with LPS. DCs were treated with control (DMSO) or 
ibrutinib (1 µM or 10 µM), washed twice and treated with LPS (1 µg/ml). After 4, 12 and 
24 hours of LPS treatment, cytokine production was determined in the culture 
supernatants by ELISA. At these time points, NO levels were determined in the culture 
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supernatants by measuring nitrite concentrations using Griess assay. The data are 
presented as mean + S.E.M of triplicate sample values from two independent 
experiments. *p < 0.05, **p < 0.001, ***p < 0.0001. 
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Figure 2. Ibrutinib enhances the induction of IL-6, IL-10, IL-18 and TGF-β in dendritic 
cells upon LPS stimulation. (A) IL-6, (B) IL-10, (C) IL-18 and (D) TGF-β mRNA induction 
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in control and ibrutinib-treated DCs upon LPS stimulation. DCs were treated with control 
(DMSO) or ibrutinib (1 µM or 10 µM), washed twice and treated with LPS (1 µg/ml). 
After 4, 12 and 24 hours of LPS treatment, cells were treated with TRIzol Reagent, RNA 
was isolated from cells and mRNA levels of respective cytokines were determined by 
real-time qPCR.  The data are presented as mean + S.E.M of duplicates obtained by 
pooling three samples in two independent experiments. *p < 0.05. 
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Figure 3. Ibrutinib differentially regulates the surface expression of MHC-II and co-
stimulatory molecules in LPS-treated dendritic cells. Histogram plots show expressions 
of (A) MHC-II, (B) CD86 and (C) CD80 in LPS/control and LPS/ibrutinib-treated DC 
cultures.  Numbers represent mean percentage of cells + S.E.M of the respective 
surface molecule on DCs. The data presented are representative plots of three 
independent experiments. Mean fluorescence intensities (MFIs) of (D) MHC-II, (E) 
CD86 and (F) CD80 expression in LPS/control and LPS/ibrutinib-treated DC cultures. 
The data are presented as mean + S.E.M of representative MFI values of three 
independent experiments. DCs were treated with control (DMSO) or ibrutinib (1 µM), 
washed twice and treated with LPS (1 µg/ml). After 24 hours of LPS treatment, cells 
were blocked, stained with conjugated antibodies for the respective surface molecules 
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and expressions of the surface molecules were determined by flow cytometry. Analyses 
were conducted by gating on CD11c+ DCs. *p < 0.05, **p < 0.001, ***p < 0.0001. 
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Figure 4. Ibrutinib treated DCs promote IL-17 response upon culture with T cells. (A) 
Analysis of T cell proliferation upon co-culture with control-, ibrutinib-, LPS/control- or 
LPS/ibrutinib-treated DCs. DCs were treated with control (DMSO) or ibrutinib (1 µM), 
washed twice, pulsed with OVA (10 µg/ml) for 2 hours and treated with LPS (1 µg/ml) 
for 22 hours. After OVA/LPS stimulation, DCs were cultured in 1:4 ratio with CFSE-
stained T cells enriched from spleens of OT-II mice for 5 days. At Day 5, cells from co-
culture were blocked, stained with anti-CD4 antibody and T cell proliferation was 
measured by flow cytometry. Analyses were conducted by gating on CD4+ population. 
The data are presented as mean + S.E.M of duplicates and are representative of two 
independent experiments. (B) Production of T cell cytokines IL-17, (C) IFN-γ and (D) IL-
13 in co-culture experiments performed as mentioned in A. At Day 5 of co-culture, cell 
culture supernatants were collected and the respective cytokines were measured by 
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ELISA. The data are presented as mean + S.E.M of duplicates and are representative 
of two independent experiments. *p < 0.05, **p < 0.001.  
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